Priothera
Description: Priothera develops oral S1P receptor modulators to enhance HSCT outcomes for hematological malignancies, improving patient lives.
Country: Ireland
Based in: Dublin
Founded: 2020
Funding Stage: Series A/B
Tags: ['clinical-stage', 'hematological', 'sphingosine']
ACCESS DIRECTORY
Details about how we process your information are available in our Privacy Policy.
